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OBJECTIVES We sought to determine the effect of varying degrees of renal insufficiency on death and
cardiac events during and after a percutaneous coronary intervention (PCI).
BACKGROUND Patients with end-stage renal disease have a high mortality from coronary artery disease. Little
is known about the impact of mild and moderate renal insufficiency on clinical outcomes after
PCI.
METHODS Cardiac mortality and all-cause mortality were determined for 5,327 patients undergoing PCI
from January 1, 1994, to August 31, 1999, at the Mayo Clinic, based on the estimated
creatinine clearance or whether the patient was on dialysis.
RESULTS In-hospital mortality was significantly associated with renal insufficiency (p  0.001). Even
after successful PCI, one-year mortality was 1.5% when the creatinine clearance was 70
ml/min (n  2,558), 3.6% when it was 50 to 69 ml/min (n  1,458), 7.8% when it was 30
to 49 ml/min (n 828) and 18.3% when it was30 ml/min (n 141). The 18.3% mortality
rate for the group with 30 ml/min creatinine clearance was similar to the 19.9% mortality
rate in patients on dialysis (n  46). The mortality risk was largely independent of all other
factors.
CONCLUSIONS Renal insufficiency is a strong predictor of death and subsequent cardiac events in a
dose-dependent fashion during and after PCI. Patients with renal insufficiency have more
baseline cardiovascular risk factors, but renal insufficiency is associated with an increased risk
of death and other adverse cardiovascular events, independent of all other measured
variables. (J Am Coll Cardiol 2002;39:1113–9) © 2002 by the American College of
Cardiology Foundation
Chronic renal failure is associated with a high cardiovascular
mortality. The mortality rate in the first year after initiation
of dialysis is 24% (1). Over half of these deaths are
attributable to cardiovascular diseases. Although much is
known about the effects of end-stage renal failure on
coronary artery disease (CAD), little is known about the
impact of mild renal insufficiency on CAD. Nearly 11
million Americans have mild renal insufficiency—over 30
times the number of people in the dialysis population—and
this number continues to grow (2). Thus, further under-
standing of the coronary risks and outcomes of patients with
mild renal insufficiency is necessary.
The clinical outcome of patients with end-stage renal
disease undergoing a percutaneous coronary intervention
(PCI) is poor (3,4). Balloon angioplasty is a feasible type of
PCI, but it is associated with a 60% to 81% incidence of
restenosis (3–5). Despite this high incidence of restenosis,
symptoms of restenosis are often absent, and severe silent
ischemia may account for the high cardiac mortality in this
population. The clinical outcome after PCI in patients with
mild renal insufficiency is unknown.
We sought to determine the mortality, cardiac-specific
mortality and risk of other adverse coronary events as
functions of creatinine clearance in patients undergoing
PCI. Furthermore, we analyzed the impact of renal insuf-
ficiency on mortality after adjusting for other cardiovascular
risk factors.
METHODS
Mayo Clinic PCI Registry. All patients undergoing PCI
at the Mayo Clinic in Rochester, Minnesota, since 1979 are
prospectively followed, and data are entered in a registry
based on a protocol approved by the Institutional Review
Board. This registry includes baseline demographic, clinical
and angiographic data. Follow-up data are collected by
telephone, using a standardized questionnaire, at six
months, one year and then annually after the procedure. All
adverse events are confirmed by reviewing the medical
records of the patients followed at our institution and by
contacting the patients’ physicians and reviewing the hos-
pital records of patients followed elsewhere.
Current study. In the current study, all patients who
underwent PCI between January 1, 1994, and August 31,
1999, at the Mayo Clinic were eligible for inclusion. For
patients who underwent more than one revascularization
procedure during the study period, only the first interven-
tion was included for analysis. Patients were excluded if they
had undergone renal transplantation (n  5), had acute
renal failure before the PCI procedure (as defined by a rise
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in serum creatine of 1 mg/dl above the baseline value) (n 
21), did not have their creatinine level measured at the
Mayo Clinic before the procedure (n  638) or were
undergoing PCI within 24 h after myocardial infarction
(MI) or had pre-procedural shock (n  1,208). All patients
who denied research authorization were also excluded (n 
133). The specific type of revascularization procedure (i.e.,
balloon angioplasty, atherectomy, stenting) was chosen by
the interventional cardiologist.
Assessment of renal function. Using the creatinine level
obtained closest to the time of, but before, the angiogram,
renal function was assessed by the estimated creatinine
clearance, using the Cockroft-Gault formula: creatinine
clearance (ml/min)  [([140  age]  weight [kg])/72 
serum creatinine (mg/dl)] ( 0.85 for women) (6). This
equation has a close correlation with measured creatinine
clearances (correlation coefficient 0.83) and gives a more
accurate assessment of renal function than serum creatinine
alone. Patients on hemodialysis or peritoneal dialysis were
analyzed separately. Patients were categorized either by level
of creatinine clearance (70, 50 to 69, 30 to 49 and
30 ml/min) or on-dialysis status.
Angiographic analysis. The severity of coronary stenosis
was determined by two observers using visual assessment or
by hand-held calipers by means of orthogonal views.
Definitions. The number of diseased coronary arteries was
defined by the number of major coronary arteries with
luminal diameter stenosis 70%. Patients with 50%
stenosis in the left main coronary artery were considered to
have two-vessel disease if there was right dominance and
three-vessel disease if there was left dominance.
Angiographic success was defined as PCI with 20%
improvement in luminal diameter stenosis of at least one
treatment site, with residual stenosis 50%. Procedural
success was defined as angiographic success without death,
Q-wave MI or coronary artery bypass graft surgery (CABG)
during the initial hospitalization. Complete revasculariza-
tion was achieved if there were no remaining stenoses
70%. Myocardial infarction was defined by the presence of
two of three criteria: chest pain, electrocardiographic
changes and increased cardiac enzyme levels at least twice
the upper limit of the normal range. Myocardial infarctions
were identified as being Q-wave or non–Q-wave, whenever
possible. The frequency of MI included all patients with
Q-wave or non–Q-wave MI and, in rare cases, MI that
could not be classified as Q-wave or non–Q-wave. To
determine the causes of death, autopsy and medical records
were reviewed when available, and family members were
interviewed when such records were not available. Cardiac
death was considered to have occurred if death occurred
suddenly and autopsy failed to reveal another cause or if
death was associated with documented MI or other cardiac
causes such as congestive heart failure and arrhythmia.
Statistical analysis. Data are presented as the mean value
 SD or as a percentage. All analyses were performed using
SAS software (SAS, Inc., Cary, North Carolina). Compar-
isons between groups were made by one-way analysis of
variance, the Pearson chi-square test or the log-rank test.
All tests of significance were two-tailed. Using the Kaplan-
Meier method, event-free survival curves were constructed.
Estimated risk ratios of follow-up death were determined
for creatinine clearance analyzed as a continuous variable.
Using variables significantly associated with mortality on
univariate analysis, a multivariable model was created. This
model was then simplified using backward selection. To
estimate the effect of creatinine clearance, this variable was
added to the previously selected model. Creatinine clearance
was treated as a numerical variable with the potential for
quadratic (curved) effects. Creatinine values for dialysis
patients were ignored and forced to the reference level. A
separate variable for dialysis treatment was included to
estimate its effect. P values 0.05 were considered signifi-
cant.
RESULTS
Baseline characteristics. The baseline characteristics of
the 5,327 patients who underwent PCI (study population),
grouped by estimated creatinine clearance or the need for
dialysis, are shown in Table 1. The majority of dialysis
patients (89%) were on hemodialysis; 11% were on perito-
neal dialysis. Patients with a lower creatinine clearance were
more likely to be older, women, diabetic and hypertensive,
with less height and weight. Such patients more commonly
had previous strokes, peripheral vascular disease, previous
CABG and a lower left ventricular ejection fraction. Dial-
ysis patients more frequently had diabetes mellitus, hyper-
tension and peripheral vascular disease.
The most common indication for PCI was unstable
angina in all groups. However, patients with the lowest
creatinine clearance more frequently presented with a recent
MI (7 days) or with congestive heart failure as the
indication for their procedure. Furthermore, patients under-
going dialysis were more likely to have ischemia on a
functional test without angina than patients with milder
renal insufficiency.
Angiographic analysis. Patients with a lower creatinine
clearance more frequently had multivessel disease, vein graft
disease, more complex lesions (according to the modified
American College of Cardiology/American Heart Associa-
tion classification) and greater use of rotational atherectomy
(Table 2). Glycoprotein IIb/IIIa inhibitors were given
before or during the procedure in 24.4% of the interven-
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CI  confidence interval
MI  myocardial infarction
PCI  percutaneous coronary intervention
RR  risk ratio
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tions, with no difference in the frequency of use of these
agents in the different creatinine clearance groups. A dis-
section occurred 20.6% of the time, and the frequency was
similar in all groups (p  0.60). The angiographic success
rate was similar in the groups. However, patients with a
lower creatinine clearance and those on dialysis had more
frequent complications, including death, non–Q-wave MI
or the need for CABG during the hospital period, and thus
the procedural success rate was lower. Furthermore, those
patients with a lower creatinine clearance were less likely to
have been completely revascularized after the procedure.
The frequency of adverse events in the hospital and at
one-year follow-up is shown in Table 3. Patients with a
lower creatinine clearance had an increased risk of death or
MI (both Q-wave and non–Q-wave) in the hospital and in
the year following the procedure, both including and ex-
cluding the in-hospital events. Of note, the marked increase
in the frequency of in-hospital death in the lower creatinine
clearance groups and in dialysis patients was associated with
only a small increase in both Q-wave and non–Q-wave MI.
Furthermore, there was a marked increase in acute renal
failure in the lower creatinine clearance groups. The
Kaplan-Meier curves demonstrating mortality and cardiac
mortality are shown in Figures 1 and 2. The mean follow-up
time was 2.7  1.6 years. These figures demonstrate that
creatinine clearance was significantly associated with mor-
tality and cardiac mortality in patients after successful PCI.
Using a univariate model, the risk ratios (RR) for death
after successful PCI were significant (p  0.001) for all of
the following variables: creatinine clearance in 10-ml/min
units (RR 0.75, 95% confidence interval [CI] 0.7 to 0.8),
age in 10-year units (RR 1.61, 95% CI 1.5 to 1.8), weight
in 10-kg units (RR 0.86, 95% CI 0.8 to 0.9), diabetes (RR
2.43, 95% CI 2.0 to 2.9), previous MI (RR 1.68, 95% CI 1.4
to 2.0), previous stroke or transient ischemic attack (RR
2.09, 95% CI 1.7 to 2.7), congestive heart failure on
presentation (RR 5.19, 95% CI 4.2 to 6.4), peripheral
vascular disease (RR 2.93, 95% CI 2.4 to 3.6), multivessel
disease (RR 1.94, 95% CI 1.6 to 2.3), right coronary artery
intervention (RR 0.65, 95% CI 0.5 to 0.8) and vein graft
intervention (RR 2.44, 95% CI 1.9 to 3.0). In the multi-
variate model (Table 4), the RR of death during follow-up
was highest for dialysis patients, followed by patients with
moderate renal dysfunction (creatinine clearance 50 ml/
min). Moderate or severe renal insufficiency was associated
with a greater risk of death than even diabetes. The
association between renal dysfunction and death was dose-
dependant. The use of a stent was not a significant factor in
the multivariate model (p  0.10).
DISCUSSION
The principal finding of this study is that renal dysfunction
significantly increases the risk of death and cardiac death
during and after PCI in a dose-dependent manner. Even
mild renal insufficiency (creatinine clearance 70 ml/min) has
Table 1. Baseline Patient Characteristics by Estimated Creatinine Clearance or Dialysis
Characteristic
Creatinine Clearance (ml/min)
p Value*
>70
(n  2,687)
50–69
(n  1,537)
30–49
(n  899)
<30
(n  154)
Dialysis
(n  50)
Height (m) 1.74  0.09 1.69  0.09 1.65  0.09 1.63  0.10 1.69  0.09 0.001
Weight (k) 93.1  17.1 78.5  11.6 70.9  12.5 67.5  14.7 79.7  18.3 0.001
Age (years) 58.9  9.9 70.1  7.8 76.8  7.4 77.9  9.2 64.1  11.4 0.001
Male (%) 82.3 67.6 50.7 42.9 70.0 0.001
Diabetes mellitus (%) 20.4 20.8 23.8 30.5 50.0 0.001
Insulin treatment 5.6 6.6 7.5 12.1 26.8 0.001
Treatment with oral agents 6.9 7.9 7.5 9.3 4.9 0.60
Hypertension (%) 54.7 62.2 68.7 80.5 94.0 0.001
Hyperlipidemia (%) 62.7 63.0 58.0 59.3 55.8 0.11
Smoking history (%)
Past 70.2 59.5 52.9 44.4 66.0 0.001
Current 24.4 11.6 6.1 5.2 12.0 0.001
Previous PCI (%) 22.8 22.8 22.0 16.9 28.0 0.41
Previous CABG (%) 18.1 26.2 29.7 27.3 24.0 0.001
Previous myocardial infarction (%) 48.2 47.9 52.9 66.9 57.4 0.001
Previous stroke or TIA (%) 6.0 12.8 17.8 25.7 22.0 0.001
Mean LVEF (%) 60.6  13.9 58.2  16.3 54.2  16.8 47.9  17.3 56.7  13.5 0.001
Peripheral vascular disease (%) 7.5 13.5 19.0 23.0 57.4 0.001
Indications for PCI (%)
Unstable angina 72.6 72.9 72.6 75.3 64.0 0.65
Stable angina 12.9 13.3 12.1 7.8 10.0 0.33
Myocardial infarction within 7 days 19.3 16.2 19.5 26.6 10.0 0.003
Positive functional test without angina 7.0 7.7 8.5 6.5 22.0 0.002
Congestive heart failure 3.6 7.5 14.7 31.8 16.0 0.001
*Difference between the creatinine clearance groups. Data are presented as the mean value  SD or percentage of patients.
CABG  coronary artery bypass graft surgery; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary intervention; TIA  transient ischemic attack.
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an important association with one-year mortality (relative
risk 1.46) and is nearly as predictive as diabetes mellitus.
Moderate renal failure (creatinine clearance 50 ml/min) has
a higher association with death than any variable, except for
congestive heart failure on presentation. Severe renal failure
has the highest association with one-year mortality, in both
patients not requiring dialysis (creatinine clearance 30 ml/
min) and those on dialysis (relative risk 3.70 and 8.91,
respectively). In this study, the use of a stent did not
significantly alter the high mortality of patients with renal
insufficiency.
Renal failure and cardiovascular risk factors. The asso-
ciation between renal failure and CAD is well established,
but the precise mechanisms of this interaction are not clearly
understood. Explanations of this interaction include the
greater frequency of risk factors, such as diabetes mellitus
and hypertension, in patients with renal insufficiency, as well
as the effects of renal failure on lipids, oxidative stress,
homocysteine and fibrinogen (7–10).
Diabetes mellitus and hypertension are the leading causes
of end-stage renal disease (11). Previous studies have dem-
onstrated that the increased prevalence of CAD in patients
on dialysis or with chronic renal insufficiency is partly due to
the increased presence of these well-established cardiac risk
factors (7,12,13). In our study, patients with renal dysfunc-
tion had a greater number of diseased coronary vessels.
Diabetes mellitus and hypertension were associated with
progressive renal dysfunction and also with the extent and
severity of CAD. However, when renal failure is treated
with renal transplantation, the risk of future cardiovascular
events decreases, despite the persistence of these high-risk
characteristics (1). Thus, advanced renal dysfunction inde-
pendently contributes to cardiovascular mortality and in-
creased cardiac risk. In our study, even mild renal insuffi-
ciency doubled the risk of death at one year.
Despite the association of diabetes mellitus and hyper-
tension with renal dysfunction, our study did not identify an
association with hyperlipidemia (defined as total cholesterol
240 mg/dl). Although total cholesterol levels were not
increased with renal dysfunction in our study population,
lipid profiles tend to be more atherogenic in patients with
renal insufficiency, even when patients are not hyperlipid-
emic (14,15). Renal dysfunction increases homocysteine and
oxidative stress, which enhance the oxidation of low-density
lipoprotein, making it even more atherogenic (16,17). Hy-
perhomocysteinemia also promotes atherosclerotic plaque
Table 2. Angiographic and Procedural Characteristics of the Study Population
Characteristic
Creatinine Clearance (ml/min)
p
Value*
>70
(n  2,687)
50–69
(n  1,537)
30–49
(n  899)
<30
(n  154)
Dialysis
(n  50)
No. of coronary vessels diseased (%) 0.001
One 51.5 46.9 39.3 28.3 31.3
Two 34.3 36.1 38.1 36.6 37.5
Three 12.1 15.2 20.2 34.5 29.2
Coronary vessels treated (%) 0.69
One 84.6 83.6 83.6 87.0 76.0
Two 14.7 15.8 15.7 12.3 24.0
Three 0.7 0.6 0.7 0.6 0.0
Coronary vessels treated (%)
LAD 42.9 40.3 42.7 37.7 28.0 0.09
LCx 28.7 29.1 25.7 29.8 26.0 0.41
RCA 35.4 33.7 31.4 26.6 50.0 0.006
LMCA 1.5 1.6 2.2 3.2 4.0 0.23
Vein graft 7.0 11.7 14.3 16.9 18.0 0.001
IMA 0.7 0.3 0.8 0.0 2.0 0.25
Modified ACC/AHA lesion class (%)† 0.001
A 2.5 2.2 1.8 1.1 1.5
B1 18.7 16.2 13.0 13.1 10.9
B2 38.3 37.3 33.2 33.7 31.4
C 40.5 44.3 52.0 52.0 56.2
Device used (%)
Balloon angioplasty alone 26.6 26.1 28.9 31.2 24.0 0.38
Stent 68.6 68.0 65.3 64.3 68.0 0.39
Directional atherectomy 2.4 1.6 1.3 0.0 4.0 0.04
Rotational atherectomy 7.0 9.2 10.2 11.0 16.0 0.002
Laser 1.0 1.4 0.9 0.6 0.0 0.56
Angiographic success (%)† 96.0 95.4 95.4 97.8 95.0 0.16
Procedural success (%) 95.2 94.9 92.1 91.6 92.0 0.003
Complete revascularization (%) 55.0 51.4 45.1 28.6 40.0 0.001
*Difference between the creatinine clearance groups. †Denominator is the number of lesions attempted.
ACC/AHA American College of Cardiology/American Heart Association; IMA internal mammary artery; LAD left
anterior descending coronary artery; LCx  left circumflex coronary artery; LMCA  left main coronary artery; RCA  right
coronary artery.
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formation by increasing free apolipoprotein(a) (9,18). Thus,
regardless of the similar rates of hyperlipidemia between the
groups in our study, the atherogenic risk of cholesterol is
higher in patients with renal dysfunction.
Percutaneous coronary interventions in patients with
chronic renal failure. Management of CAD in patients on
dialysis or with mild renal insufficiency is more difficult than
that in patients with normal renal function. Medical man-
agement in patients with renal dysfunction has been based
on therapy shown to be beneficial in other patient popula-
tions. Currently, these medications include aspirin, beta-
blockers, nitrates, hydroxymethylglutaryl coenzyme A re-
ductase inhibitors (statins) and angiotensin-converting
enzyme inhibitors. However, because of the routine exclu-
sion of this patient population from clinical trials, the
efficacy of these agents in patients with renal dysfunction is
not proven.
Treatment of CAD by PCI in patients with chronic renal
failure is feasible but is associated with poor long-term
results (3,5). Restenosis rates are as high as 60% to 81%
when evaluated by repeat angiography. However, clinical
restenosis is not increased in patients with chronic renal
failure, compared with patients with normal renal function
(19). Thus, the absence of symptoms of restenosis in
patients with chronic renal failure may lead to severe silent
ischemia and contribute to the high risk of subsequent
cardiac events. Other studies have not evaluated the role of
stenting in patients with renal insufficiency. In our study
population, stenting did not significantly improve survival
after a successful intervention. In the only randomized study
of dialysis patients comparing an invasive revascularization
approach (including both PCI and CABG) with medical
therapy, the invasive approach had a clear survival benefit
(20). However, the medical therapy consisted of a calcium
channel blocker and aspirin, which does not reflect current
practice. Moreover, this study only evaluated diabetic pa-
tients on dialysis, which further limits the applicability of
this study. With regard to milder renal insufficiency, little is
known about the clinical outcome of patients after PCI.
Such patients have been excluded from randomized studies.
Increased restenosis after PCI in patients with mild renal
insufficiency may account for part of the increased mortality
rate after PCI in this population.
Coronary artery bypass graft surgery in patients with
chronic renal failure. Coronary artery bypass graft surgery
is also associated with a poor outcome in patients with
chronic renal failure, with in-hospital mortality rates as high
as 20% (21,22). Even mild renal insufficiency is associated
with a doubling of hospital mortality after CABG (23).
Coronary artery disease is more diffuse in patients with renal
dysfunction, which undoubtedly contributes to the higher
complication rate and worse outcomes after interventions.
Table 3. Adverse Events During the Initial Hospitalization and at One Year
Event
Creatinine Clearance (ml/min)
p
Value*
>70
(n  2,687)
50–69
(n  1,537)
30–49
(n  899)
<30
(n  154)
Dialysis
(n  50)
In-hospital events (%)
Death 0.5 0.7 2.3 7.1 6.0 0.001
Q-wave MI 0.7 0.8 1.8 0.6 0.0 0.03
CABG 1.3 1.4 1.6 0.0 0.0 0.54
Death, Q-wave MI or CABG 2.4 2.7 5.1 7.8 6.0 0.001
Non–Q-wave MI 4.7 6.1 7.3 4.5 2.0 0.02
Stroke or TIA 0.2 0.5 0.4 0.6 0.0 0.63
Acute renal failure 0.1 0.3 2.0 6.5 0.0 0.001
Subsequent events at 1 year (%)
Death 1.5 3.6 7.8 18.3 19.9 0.001
Q-wave MI 0.2 0.3 0.1 0.0 2.4 0.04
Non–Q-wave MI 1.8 2.4 2.0 7.5 9.9 0.001
Any MI 2.9 3.5 4.1 8.3 14.4 0.001
Target vessel revascularization
PTCA (same lesion) 10.1 10.9 8.7 7.5 12.9 0.41
CABG 5.7 5.5 4.6 3.1 2.5 0.51
Any of the above 16.6 19.2 20.0 29.6 35.3 0.001
Cumulative events at 1 year (%)
Death 2.1 4.2 10.0 25.3 24.4 0.001
Q-wave MI 0.9 1.1 1.9 0.6 2.4 0.02
Non–Q-wave MI 6.3 8.3 9.0 11.9 11.6 0.004
Any MI 8.4 10.3 13.0 14.5 17.8 0.001
Target vessel revascularization
PTCA (same lesion) 11.6 12.1 9.9 7.1 12.5 0.24
CABG 7.1 6.6 6.2 3.1 2.4 0.29
Any of the above 23.2 26.2 30.4 38.1 38.5 0.001
*Difference between the creatinine clearance groups.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty; TIA  transient ischemic attack.
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Newer surgical techniques, such as the minimally invasive
direct CABG, have been successful in high-risk patients
with renal failure, but the long-term results, compared with
other surgical and non-surgical techniques, have yet to be
determined (24). When comparing PCI with CABG in
patients on dialysis, retrospective studies suggest that
CABG improves survival (25,26). Because these studies
were retrospective, the bias toward treatment allocation
limits the usefulness of these results. No studies have
compared CABG or PCI with medical therapy in more
mild forms of renal insufficiency. Thus, a better understand-
ing of treatment options in patients with established CAD
is necessary in patients with chronic renal failure and renal
insufficiency.
Conclusions. Our study demonstrates that after PCI, renal
dysfunction is independently associated with mortality and
other adverse events during and after PCI, in a dose-
dependent manner. This increased risk occurs even when
Figure 1. All-cause mortality after successful percutaneous coronary intervention in patients, based on their estimated creatinine clearance.
Figure 2. Cardiac mortality after successful percutaneous coronary intervention in patients, based on their estimated creatinine clearance.
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renal insufficiency is mild, with a doubling of mortality at
one year. More marked renal dysfunction exceeds the risk
associated with diabetes mellitus and other cardiac risk
factors. Further studies are needed to identify the most
appropriate treatments of CAD in patients with renal
insufficiency.
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Table 4. Estimated Risk Ratios for Death in Patients With
Successful Percutaneous Revascularization Procedures
Variable
Risk Ratio
(95% CI) p Value
Creatinine clearance, linear 0.001
Creatinine clearance, quadratic 0.001
90 1.00 (reference)
70 1.46 (1.3–1.6)
50 2.25 (1.8–2.9)
30 3.70 (2.5–5.5)
Dialysis 8.91 (5.3–15.0) 0.001
Age (in 10-year units) 1.11 (1.0–1.3) 0.09
Weight (in 10-kg units) 1.07 (1.0–1.2) 0.08
Diabetes mellitus 1.66 (1.3–2.0) 0.001
Previous myocardial infarction 1.23 (1.0–1.5) 0.04
Previous stroke or transient
ischemic attack
1.29 (1.0–1.65) 0.05
Congestive heart failure on
presentation
2.79 (2.2–3.5) 0.001
Peripheral vascular disease 1.46 (1.2–1.8) 0.002
Multivessel disease 1.57 (1.3–1.9) 0.001
Right coronary artery intervention 0.72 (0.6–0.9) 0.005
Vein graft intervention 1.39 (1.1–1.8) 0.01
Stents 0.85 (0.7–1.03) 0.10
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